<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37924387</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2523-899X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current medical science</Title><ISOAbbreviation>Curr Med Sci</ISOAbbreviation></Journal><ArticleTitle>Hyperbaric Oxygen Treatment for Long COVID: From Molecular Mechanism to Clinical Practice.</ArticleTitle><Pagination><StartPage>1061</StartPage><EndPage>1065</EndPage><MedlinePgn>1061-1065</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11596-023-2799-1</ELocationID><Abstract><AbstractText>Long COVID symptoms typically occur within 3 months of an initial COVID-19 infection, last for more than 2 months, and cannot be explained by other diagnoses. The most common symptoms include fatigue, dyspnea, coughing, and cognitive impairment. The mechanisms of long COVID are not fully understood, but several hypotheses have been put forth. These include coagulation and fibrosis pathway activation, inflammatory and autoimmune manifestations, persistent virus presence, and Epstein-Barr virus reactivation. Hyperbaric oxygen therapy (HBOT) is a therapeutic method in which a person inhales 100% oxygen under pressure greater than that of the atmosphere. HBOT has some therapeutic effects, including improvement of microcirculation, inhibition of cytokine release leading to a reduction in inflammatory responses, inhibition of autoimmune responses, and promotion of neurological repair. Several clinical trials have been carried out using HBOT to treat long COVID. The results suggest that HBOT helps to improve symptom severity, reduce symptom duration, and enhance patients' quality of life. It is believed that HBOT is an effective option for patients with long COVID, which is worth actively promoting.</AbstractText><CopyrightInformation>&#xa9; 2023. Huazhong University of Science and Technology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jian-Qing</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Hyperbaric Oxygen, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, China. panjianqingsz@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Zhi-Min</ForeName><Initials>ZM</Initials><AffiliationInfo><Affiliation>BGI-Shenzhen, Shenzhen, 518083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Lian-Bi</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Hyperbaric Oxygen, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Curr Med Sci</MedlineTA><NlmUniqueID>101729993</NlmUniqueID><ISSNLinking>2523-899X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="Y">Hyperbaric Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">hyperbaric oxygen therapy</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>4</Day><Hour>21</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>4</Day><Hour>12</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37924387</ArticleId><ArticleId IdType="doi">10.1007/s11596-023-2799-1</ArticleId><ArticleId IdType="pii">10.1007/s11596-023-2799-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet, 2022,400(10350):452&#x2013;461</Citation><ArticleIdList><ArticleId IdType="pubmed">35934007</ArticleId><ArticleId IdType="pmc">9352274</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ, 2022,377:e069676</Citation><ArticleIdList><ArticleId IdType="pubmed">35584816</ArticleId><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, et al. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ, 2021,372:n136</Citation><ArticleIdList><ArticleId IdType="pubmed">33483331</ArticleId><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine, 2023,55:101762</Citation><ArticleIdList><ArticleId IdType="pubmed">36474804</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S, Abbafati C, Aerts JG, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA, 2022,328(16):1604&#x2013;1615</Citation><ArticleIdList><ArticleId IdType="pubmed">36215063</ArticleId><ArticleId IdType="pmc">9552043</ArticleId><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. Health outcomes in people years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med, 2022,10(9):863&#x2013;876</Citation><ArticleIdList><ArticleId IdType="pubmed">35568052</ArticleId><ArticleId IdType="pmc">9094732</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med, 2022,28(11):2398&#x2013;2405</Citation><ArticleIdList><ArticleId IdType="pubmed">36357676</ArticleId><ArticleId IdType="pmc">9671810</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med, 2022,28(8):1706&#x2013;1714</Citation><ArticleIdList><ArticleId IdType="pubmed">35879616</ArticleId><ArticleId IdType="pmc">9388369</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I, Fonseca-Rodriguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ, 2022,377: e069590</Citation><ArticleIdList><ArticleId IdType="pubmed">35387772</ArticleId><ArticleId IdType="doi">10.1136/bmj-2021-069590</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost, 2021,19(10):2546&#x2013;2553</Citation><ArticleIdList><ArticleId IdType="pubmed">34375505</ArticleId><ArticleId IdType="doi">10.1111/jth.15490</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Ward SE, Townsend L, et al. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost, 2022,20(10):2429&#x2013;2438</Citation><ArticleIdList><ArticleId IdType="pubmed">35875995</ArticleId><ArticleId IdType="pmc">9349977</ArticleId><ArticleId IdType="doi">10.1111/jth.15830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol, 2022,21(1):148</Citation><ArticleIdList><ArticleId IdType="pubmed">35933347</ArticleId><ArticleId IdType="pmc">9356426</ArticleId><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol, 2022,23(2):210&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci, 2021,14(2): 502&#x2013;508</Citation><ArticleIdList><ArticleId IdType="pubmed">32989903</ArticleId><ArticleId IdType="pmc">7536986</ArticleId><ArticleId IdType="doi">10.1111/cts.12908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature, 2021,595(7866):283&#x2013;288</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovarik JJ, Bileck A, Hagn G, et al. A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome. iScience, 2023,26(1):105717</Citation><ArticleIdList><ArticleId IdType="pubmed">36507225</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2022.105717</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci, 2021,24(3):368&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pubmed">33328624</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00771-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere JJ, Serafini RA, Pryce KD, et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci Transl Med, 2022,14(664):eabq3059</Citation><ArticleIdList><ArticleId IdType="pubmed">35857629</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abq3059</ArticleId></ArticleIdList></Reference><Reference><Citation>Soung AL, Vanderheiden A, Nordvig AS, et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain, 2022,145(12): 4193&#x2013;4201</Citation><ArticleIdList><ArticleId IdType="pubmed">36004663</ArticleId><ArticleId IdType="pmc">9452175</ArticleId><ArticleId IdType="doi">10.1093/brain/awac270</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T. Neurological infection with SARS-CoV-2 - the story so far. Nat Rev Neurol, 2021,17(2):65&#x2013;66</Citation><ArticleIdList><ArticleId IdType="pubmed">33414554</ArticleId><ArticleId IdType="pmc">7789883</ArticleId><ArticleId IdType="doi">10.1038/s41582-020-00453-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol, 2020,19(11):919&#x2013;929</Citation><ArticleIdList><ArticleId IdType="pubmed">33031735</ArticleId><ArticleId IdType="pmc">7535629</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 2022,612(7941):758&#x2013;763</Citation><ArticleIdList><ArticleId IdType="pubmed">36517603</ArticleId><ArticleId IdType="pmc">9749650</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Xiao J, Sun R, et al. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg Infect Dis, 2020,26(8):1834&#x2013;1838</Citation><ArticleIdList><ArticleId IdType="pubmed">32383638</ArticleId><ArticleId IdType="pmc">7392422</ArticleId><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm LK, Nielsen SSF, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine, 2021,64:103230</Citation><ArticleIdList><ArticleId IdType="pubmed">33530000</ArticleId><ArticleId IdType="pmc">7847186</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103230</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest, 2023,133(3): e163669</Citation><ArticleIdList><ArticleId IdType="pubmed">36454631</ArticleId><ArticleId IdType="pmc">9888380</ArticleId><ArticleId IdType="doi">10.1172/JCI163669</ArticleId></ArticleIdList></Reference><Reference><Citation>Godman CA, Chheda KP, Hightower LE, et al. Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. Cell Stress Chaperones, 2010,15(4):431&#x2013;442</Citation><ArticleIdList><ArticleId IdType="pubmed">19949909</ArticleId><ArticleId IdType="doi">10.1007/s12192-009-0159-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregorevic P, Lynch GS, Williams DA. Hyperbaric oxygen modulates antioxidant enzyme activity in rat skeletal muscles. Eur J Appl Physiol, 2001,86(1):24&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">11820317</ArticleId><ArticleId IdType="doi">10.1007/s004210100503</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson RM, Minter LM, Osborne BA, et al. Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocytemacrophages. Clin Exp Immunol, 2003,134(1):57&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pubmed">12974755</ArticleId><ArticleId IdType="pmc">1808843</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2249.2003.02248.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon BI, Kim HR, Choi EJ, et al. Attenuation of collagen-induced arthritis by hyperbaric oxygen therapy through altering immune balance in favor of regulatory T cells. Undersea Hyperb Med, 2017,44(4):321&#x2013;330</Citation><ArticleIdList><ArticleId IdType="pubmed">28783888</ArticleId><ArticleId IdType="doi">10.22462/7.8.2017.4</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YJ, Wang XL, Yu XH, et al. Hyperbaric oxygen induces endogenous neural stem cells to proliferate and differentiate in hypoxic-ischemic brain damage in neonatal rats. Undersea Hyperb Med, 2008,35(2):113&#x2013;129</Citation><ArticleIdList><ArticleId IdType="pubmed">18500076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutsaeva DR, Suliman HB, Carraway MS, et al. Oxygen-induced mitochondrial biogenesis in the rat hippocampus. Neuroscience, 2006,137(2):493&#x2013;504</Citation><ArticleIdList><ArticleId IdType="pubmed">16298077</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2005.07.061</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CH, Kim KY, Bushong EA, et al. Transcellular degradation of axonal mitochondria. Proc Natl Acad Sci USA, 2014,111(26):9633&#x2013;9638</Citation><ArticleIdList><ArticleId IdType="pubmed">24979790</ArticleId><ArticleId IdType="pmc">4084443</ArticleId><ArticleId IdType="doi">10.1073/pnas.1404651111</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganini M, Bosco G, Perozzo FAG, et al. The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review. Adv Exp Med Biol, 2021,1289:27&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">32696443</ArticleId><ArticleId IdType="doi">10.1007/5584_2020_568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Sen S. Therapeutic effects of hyperbaric oxygen: integrated review. Med Gas Res, 2021,11(1):30&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">33642335</ArticleId><ArticleId IdType="pmc">8103971</ArticleId><ArticleId IdType="doi">10.4103/2045-9912.310057</ArticleId></ArticleIdList></Reference><Reference><Citation>Harch PG. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure. Med Gas Res, 2020,10(2):61&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pubmed">32541128</ArticleId><ArticleId IdType="pmc">7885706</ArticleId><ArticleId IdType="doi">10.4103/2045-9912.282177</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T, Gonevski M, Clark C, et al. Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond), 2021,21(6):e629&#x2013;e632</Citation><ArticleIdList><ArticleId IdType="pubmed">34862223</ArticleId><ArticleId IdType="doi">10.7861/clinmed.2021-0462</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalogna M, Sasson E, Hadanny A, et al. Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: A randomized, sham-controlled trial. Neuroimage Clin, 2022,36:103218</Citation><ArticleIdList><ArticleId IdType="pubmed">36208548</ArticleId><ArticleId IdType="pmc">9528018</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2022.103218</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep, 2022,12(1):11252</Citation><ArticleIdList><ArticleId IdType="pubmed">35821512</ArticleId><ArticleId IdType="pmc">9276805</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-15565-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zant AE, Figueroa XA, Paulson CP, et al. Hyperbaric oxygen therapy to treat lingering COVID-19 symptoms. Undersea Hyperb Med, 2022,49(3):333&#x2013;339</Citation><ArticleIdList><ArticleId IdType="pubmed">36001566</ArticleId><ArticleId IdType="doi">10.22462/05.06.2022.7</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Abdel-Halim L, Hassler A, et al. Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open, 2022,12(11):e061870</Citation><ArticleIdList><ArticleId IdType="pubmed">36323462</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2022-061870</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunn AVW, Guy GW, Brysch W, et al. Understanding Long COVID; Mitochondrial Health and Adaptation-Old Pathways, New Problems. Biomedicines, 2022,10 (12):3113</Citation><ArticleIdList><ArticleId IdType="pubmed">36551869</ArticleId><ArticleId IdType="pmc">9775339</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10123113</ArticleId></ArticleIdList></Reference><Reference><Citation>Schottlender N, Gottfried I, Ashery U. Hyperbaric Oxygen Treatment: Effects on Mitochondrial Function and Oxidative Stress. Biomolecules, 2021,11(12):1827</Citation><ArticleIdList><ArticleId IdType="pubmed">34944468</ArticleId><ArticleId IdType="pmc">8699286</ArticleId><ArticleId IdType="doi">10.3390/biom11121827</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Kilic G, Li W, et al. Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19. Front Immunol, 2022, 13:838132</Citation><ArticleIdList><ArticleId IdType="pubmed">35464396</ArticleId><ArticleId IdType="pmc">9022455</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.838132</ArticleId></ArticleIdList></Reference><Reference><Citation>Balnis J, Madrid A, Hogan KJ, et al. Persistent blood DNA methylation changes one year after SARS-CoV-2 infection. Clin Epigenetics, 2022,14(1):94</Citation><ArticleIdList><ArticleId IdType="pubmed">35871090</ArticleId><ArticleId IdType="pmc">9308917</ArticleId><ArticleId IdType="doi">10.1186/s13148-022-01313-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Li W, Wang T, et al. Accelerated biological aging in COVID-19 patients. Nat Commun, 2022,13(1):2135</Citation><ArticleIdList><ArticleId IdType="pubmed">35440567</ArticleId><ArticleId IdType="pmc">9018863</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-29801-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongelli A, Barbi V, Gottardi Zamperla M, et al. Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors. Int J Mol Sci, 2021,22(11):6151</Citation><ArticleIdList><ArticleId IdType="pubmed">34200325</ArticleId><ArticleId IdType="pmc">8201243</ArticleId><ArticleId IdType="doi">10.3390/ijms22116151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmo Y, Hadanny A, Abu Hamed R, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging (Albany NY), 2020,12(22):22445&#x2013;22456</Citation><ArticleIdList><ArticleId IdType="pubmed">33206062</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Wu H, Gao R, et al. DNA Methylation May be Involved in the Analgesic Effect of Hyperbaric Oxygen via Regulating FUNDC1. Pain Res Manag, 2020,2020:1528362</Citation><ArticleIdList><ArticleId IdType="pubmed">32148597</ArticleId><ArticleId IdType="pmc">7049412</ArticleId><ArticleId IdType="doi">10.1155/2020/1528362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Hassler A, Bostr&#xf6;m E, et al. Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial. BMC Infect Dis, 2023,23(1):33</Citation><ArticleIdList><ArticleId IdType="pubmed">36670365</ArticleId><ArticleId IdType="pmc">9854077</ArticleId><ArticleId IdType="doi">10.1186/s12879-023-08002-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitman M, Fuchs S, Tyomkin V, et al. The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial. Sci Rep, 2023,13(1):9473</Citation><ArticleIdList><ArticleId IdType="pubmed">37301934</ArticleId><ArticleId IdType="pmc">10257166</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-36570-x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>